CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 57,975	$ 3,891
Research and development incentive receivable	209	185
Prepaid expenses and other current assets	217	165
Total current assets	58,401	4,241
Property and equipment, net	73	124
Right of use assets, net	620	1,026
Deferred tax assets	130	127
Deferred costs	379	831
Deposits	941	1,099
Total assets	60,544	7,448
Current liabilities:
Accounts payable	2,547	4,571
Accrued expenses	2,270	3,441
Deferred revenue - current portion	1,500
Lease liability - current portion	398	474
Total current liabilities	6,715	8,486
Non current liabilities:
Restricted stock liability	66	159
Deferred revenue, net of current portion	375
Lease liability, net of current portion	250	552
Total liabilities	7,406	9,197
Stockholders' equity (deficiency):
Common stock, $0.001 par value; 240,000,000 and 100,000,000 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 59,657,742 and 24,194,877 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	60	24
Additional paid-in capital	269,440	193,319
Accumulated other comprehensive income (loss)	(87)	76
Accumulated deficit	(216,275)	(195,168)
Total stockholders' equity (deficiency)	53,138	(1,749)
Total liabilities and stockholders' equity (deficiency)	$ 60,544	$ 7,448